/
DCF Valuation
Base-case fair value
$6.23
Intrinsic $8.30 · 25% MOS
Current price: $26.65
Base-case summary
Our base-case DCF for Biolife Solutions Inc (BLFS) projects 10 years of free cash flow growth at 20.0% for years 1–5 and 10.0% for years 6–10, anchored to 104.4% historical FCF growth, then applies a 2.5% perpetual growth rate and a 8.0% discount rate. Starting from the 3-year average of positive free cash flow ($7M) — TTM FCF was negative, this produces an intrinsic value of $8.30 per share. A 25% safety margin gives a fair value of $6.23, suggesting the stock is currently 77% overvalued against the $26.65 market price.
See 3 scenarios side by side
Conservative, Base, and Optimistic fair values, plus the sensitivity matrix and FCF history. Free account.
TTM FCF is negative ($0). Projecting from a negative base produces nonsensical results, so this model uses the 3-year average of positive FCF ($7M) as the base instead. Treat this valuation as a rough estimate — it assumes a return to historical profitability.
Model inputs
Free Cash Flow (3yr avg)
$7M
Cash & equivalents
$81M
Total debt
$17M
Shares outstanding
49M